Jim Simons Renaissance Technologies
Jim Simons is the founder of Renaissance Technologies, one of the most successful quantitative hedge funds in the world. Before his career in finance, he served as a mathematics professor and made significant contributions to differential geometry. Simons applied his analytical expertise to develop sophisticated, algorithm-driven trading strategies, earning consistently high returns for investors.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Zoom
ZM
|
+$806M |
| 2 |
AbbVie
ABBV
|
+$481M |
| 3 |
T-Mobile US
TMUS
|
+$464M |
| 4 |
Kroger
KR
|
+$430M |
| 5 |
Baidu
BIDU
|
+$423M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Bristol-Myers Squibb
BMY
|
+$1.35B |
| 2 |
AGN
Allergan plc
AGN
|
+$1.26B |
| 3 |
S
Sprint Corporation
S
|
+$675M |
| 4 |
Amgen
AMGN
|
+$488M |
| 5 |
Humana
HUM
|
+$450M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 23.45% |
| 2 | Technology | 16.09% |
| 3 | Consumer Staples | 10.57% |
| 4 | Consumer Discretionary | 9.95% |
| 5 | Communication Services | 9.52% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
2851
Abeona Therapeutics
ABEO
$425M
| $535K | ﹤0.01% |
7,341
+4,332
| +144% | +$299K |
|
|
YARW
2852
Yarrow Bioscience, Inc. Common Stock
YARW
$114M
| $535K | ﹤0.01% |
+86
| New | +$582K |
|
2853
MGIC Investment
MTG
$6.29B
| $533K | ﹤0.01% |
65,100
-3,597,367
| -98% | -$26.9M |
|
|
ZEN
2854
DELISTED
ZENDESK INC
ZEN
| $531K | ﹤0.01% |
6,000
-22,100
| -79% | -$1.7M |
|
2855
Invesco CurrencyShares Japanese Yen Trust
FXY
$426M
| $526K | ﹤0.01% |
+6,000
| New | +$529K |
|
|
VYNT
2856
DELISTED
Vyant Bio, Inc. Common Stock
VYNT
| $526K | ﹤0.01% |
34,700
+2,512
| +8% | +$39.2K |
|
|
TCRR
2857
DELISTED
TCR2 Therapeutics Inc. Common Stock
TCRR
| $524K | ﹤0.01% |
34,100
-17,200
| -34% | -$198K |
|
2858
Genesco
GCO
$391M
| $522K | ﹤0.01% |
24,100
-151,600
| -86% | -$2.8M |
|
2859
Schwab US Dividend Equity ETF
SCHD
$108B
| $518K | ﹤0.01% |
30,000
-27,000
| -47% | -$456K |
|
2860
Good Times Restaurants
GTIM
$15.8M
| $516K | ﹤0.01% |
419,240
+74,016
| +21% | +$71.4K |
|
2861
Organogenesis Holdings
ORGO
$226M
| $516K | ﹤0.01% |
134,500
+66,900
| +99% | +$241K |
|
2862
iShares S&P Mid-Cap 400 Growth ETF
IJK
$11.3B
| $515K | ﹤0.01% |
+9,200
| New | +$478K |
|
2863
Hyatt Hotels
H
$16.8B
| $513K | ﹤0.01% |
+10,200
| New | +$543K |
|
2864
MGP Ingredients
MGPI
$381M
| $513K | ﹤0.01% |
13,973
-52,600
| -79% | -$1.88M |
|
2865
Scansource
SCSC
$1.06B
| $513K | ﹤0.01% |
+21,310
| New | +$504K |
|
2866
Unity Bancorp
UNTY
$619M
| $513K | ﹤0.01% |
35,901
-19,000
| -35% | -$260K |
|
|
SHOE
2867
Shoe Station Group
SHOE
$420M
| $512K | ﹤0.01% |
35,000
-19,800
| -36% | -$237K |
|
2868
Invesco S&P 500 High Beta ETF
SPHB
$956M
| $512K | ﹤0.01% |
+12,800
| New | +$465K |
|
|
XIN
2869
DELISTED
Xinyuan Real Estate
XIN
| $512K | ﹤0.01% |
23,380
-3,440
| -13% | -$84.4K |
|
2870
Inuvo
INUV
$14.2M
| $511K | ﹤0.01% |
95,629
-70,708
| -43% | -$291K |
|
2871
NYLI Hedge Multi-Strategy Tracker ETF
QAI
$1.03B
| $508K | ﹤0.01% |
+16,741
| New | +$495K |
|
2872
INNOVATE Corp
VATE
$105M
| $508K | ﹤0.01% |
15,210
-13,026
| -46% | -$368K |
|
2873
RCI Hospitality Holdings
RICK
$214M
| $503K | ﹤0.01% |
36,300
-218,450
| -86% | -$2.67M |
|
2874
Cyclerion Therapeutics
CYCN
$18.4M
| $502K | ﹤0.01% |
4,250
+1,460
| +52% | +$122K |
|
2875
US Global Investors
GROW
$38.7M
| $500K | ﹤0.01% |
263,016
+144,690
| +122% | +$262K |
|
Similar funds
Jim Simons's Q2 2020 Portfolio in Review
As of Q2 2020, Jim Simons held 3,987 positions worth $116B, up 13% from $103B the previous quarter. Its ten largest holdings account for 14% of the portfolio.
Jim Simons withdrew a net $8.24B in Q2 2020, closing 596 positions and reducing 1,366 holdings. Its most notable exit was Allergan plc, an estimated $1.26B position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 23% of assets, down from 25% a quarter earlier, followed by Technology and Consumer Staples.
Against the trend, Jim Simons opened a new position in Uber worth $187M.
- Jim Simons's largest Q2 2020 buy was Uber: 6,030,316 shares worth $187M.
- Jim Simons added most to Zoom in Q2 2020, an estimated $806M increase.
- Jim Simons's biggest Q2 2020 reduction was Bristol-Myers Squibb, cutting an estimated $1.35B.
- Jim Simons fully exited Allergan plc in Q2 2020, selling an estimated $1.26B.
- Jim Simons's ten largest holdings make up 14% of its $116B portfolio in Q2 2020.
- Jim Simons opened 584 new positions and closed 596 in Q2 2020.
- Jim Simons's portfolio value rose 13% quarter-over-quarter to $116B.
Based on Renaissance Technologies's 13F filing for Q2 2020, filed 13 Aug 2020.